WO2004048449A2 - Process for manufacturing fibrin membranes - Google Patents
Process for manufacturing fibrin membranes Download PDFInfo
- Publication number
- WO2004048449A2 WO2004048449A2 PCT/IT2003/000780 IT0300780W WO2004048449A2 WO 2004048449 A2 WO2004048449 A2 WO 2004048449A2 IT 0300780 W IT0300780 W IT 0300780W WO 2004048449 A2 WO2004048449 A2 WO 2004048449A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- fibrin
- fibrin membrane
- sample
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/046—Fibrin; Fibrinogen
Definitions
- PROCESS FOR MANUFACTURING FIBRIN MEMBRANES AND FIBRIN MEMBRANES OBTAINED ACCORDING TO THIS PROCESS
- the present invention relates to the medical-surgical field, and in particular to a process for manufacturing fibrin membranes to be used as supports having high adhesiveness on human and animal tissues in cicatrisation and haemostasis processes, and a fibrin membrane obtained according to this process.
- a first remarkable advantage of the process according to the present invention is that of being quickly and simply feasible, thus providing concrete improvements, even from an economical point of view, with respect to the processes known in the art.
- a second advantage of the present process derives from the properties of the membrane obtained according to said process, which membrane is completely compatible with the organism whereon it will be applied, being totally extracted from by-products of human or animal blood plasma.
- Another advantage of the above-mentioned process resides in further properties of the resulting membrane, which shows high adhesiveness, capability of isolating a wound from external contaminant agents and of supporting the cicatrisation process in injured tissues.
- a further advantage of the above-mentioned process consists in the possibility of packaging under sterile conditions the resulting membrane and preserving it in conditions of unchanged sterility until the time of use, that is until the direct application on the wounded tissue.
- - Fig.l shows the relationship between specific tension and strain in a specimen of sample A of fibrin membrane, subjected to tensile tests.
- - FJR.2 shows the relationship between specific tension and strain in another specimen obtained from the same sample A, subjected to tensile tests.
- - Fig.3 shows an electron microscope image of said sample A.
- - Fig.4 shows an infrared spectrum of said sample A.
- - Figs.5a and 5b show the relationship between specific tension and strain in two specimens of a same sample B of fibrin membrane, subjected to tensile tests.
- - Fig.6 shows an electron microscope image of said sample B.
- 5 - Fig.7 shows an infrared spectrum of said sample B.
- Figs.8a and 8b show the relationship between specific tension and strain in two specimens of a same sample C of fibrin membrane, subjected to tensile tests.
- - Fig.9 shows an electron microscope image of said sample C.
- 0 - Fig.10 shows an infrared spectrum of said sample C.
- the inventive idea on which the present invention is based is that of having surprisingly found that, by starting from blood plasma as it is or from depleted blood plasma, it is possible to easily and cheaply obtain wholly sterilizable fibrin membranes having physical and structural properties such as to make said 5 membranes advantageously flexible, mouldable, strongly adhesive on human and animal tissues and soakable with different organic solutions, for example with disinfectant agents, cicatrising agents or drugs for controlled release formulations.
- depleted blood plasma there is meant a by-product of haemoderivative industry, consisting of plasma remainingXL . _ frojm_exteac ojns_oJ vario ⁇ s_p ⁇ antihaemophilic factor, albumin, etc..
- the process for manufacturing said fibrin membrane according to the present invention includes the following operating steps: a) adding a physiologic coagulant agent solution to depleted blood plasma,5 placed in suitable containers; b) leaving the mixture to stay up to the formation of a gelatinous blood clot; c) removing the transudate from said gelatinous blood clot until obtaining a fibrous membrane; 0 d) washing said fibrous membrane with dehydrating and softening agents; e) exsiccating said fibrous membrane; f) sterilizing said fibrous membrane.
- a solution of an anticoagulant agent such as sodium citrate
- a solution of a clotting agent such as calcium chloride, is added in an amount suitable to neutralize the amount of anticoagulant agent.
- the transudate removing step that is the removing of the supernatant containing plasmatic proteins, may include several steps in order to remove as much as possible any residues.
- substances such as inorganic salts (i.e. NaCl, NaHCO 3 , and like), that are completely compatible with human and animal organisms can be used since they are already physiologically present therein.
- the blood clot takes the appearance of a fibrous membrane. This one is washed out several times with water and further treated in dehydrating and softening baths, using for example ethanol and propane-triol, in order to absorb even the last water traces.
- the membrane thickness is a function of the layer thickness of plasma and clotting agent mixture, both being initially present in the container for forming the membrane.
- the subsequent sterilization step of the dehydrated membrane that can be performed by means of methods known to those skilled in the art, is preferably carried out:
- a gelatinous quadrangular shaped blood clot is obtained after addition of a calcium chloride solution to depleted blood plasma, being previously stabilized by sodium citrate. From such blood clot the transudate is removed by using NaCl, then washed 2-3 times with water and subsequently treated with ethanol and propane-triol. The resulting fibrin membrane is dried in hot air flow and sterilized in autoclave for 30 minutes at a temperature of 122°C.
- the fibrin membrane obtained according to the above-mentioned process shows the physical properties given in the following operative examples of the invention.
- the characterization of said membrane is carried out in cooperation with Politecnico di Milano.
- the membrane was extracted, ethanol was evaporated in hot air flow.
- the membrane was inserted into a closed gas-permeable envelope (available on sale) and then such an envelope was placed in an autoclave for 25-30 minutes at 122°C for sterilization.
- EXAMPLE 2 The rectangular shaped sample A (52 mm x 73 mm) was cut out from a human fibrin membrane obtained according to the above-mentioned process, sterilized in autoclave at 120°C and stored at room temperature.
- sample A was subjected to mechanical tensile and ultimate strength tests, as well as to morphological analysis at the electron microscope, having previously determined the thickness of the membrane.
- the specimen thickness was measured by a millesimal micrometer Mitutoyo mod. 293-561-30, S/N 7083373, provided with a friction device allowing to impose high strains with good measurement reproducibility. To avoid damaging sample A, this one was inserted between two Teflon sheets, having measured thickness equal to 0.142 mm. From the final measurement, that of both Teflon sheets was then subtracted. To check the uniformity level of the considered membrane, thickness measurements were carried out in ten different points of the membrane spaced apart between them and from the edges by about 10 mm. The detected values were as follows: Tensile tests
- sample A The mechanical properties of sample A were evaluated by monoaxial tensile tests using the equipment MTS Synergie 200 H S/N 261701/30 supplied by MTS (Minneapolis, MN, USA), provided with a cell MTS S/N 2.1279, having 100N as an end-point. From tlie sample, two test-pieces were cut out using a template, and the thicknesses thereof were then measured at the barycentre of each test-piece by using the same millesimal micrometer previously used.
- test-piece was subjected to the following process: a) Tnechanical condi imun ⁇ by ⁇ fofrmn of ⁇ o e oading ⁇ and ⁇ unlO ading" cycles between 0 and 1.2N at a sliding crossbar speed corresponding to 20 mrn/min. b) breaking strength at a sliding crossbar speed corresponding to 20 mm/min.
- Direction denotes the axis along which the tensile strength was exerted: one time along the axis corresponding to the specimen length, another time along the axis corresponding to its width; T (N/mm), or specific tension, denotes the ratio between the force applied to the specimen and its width unit (1 mm); e (%), or strain, means the percent ratio between the elongation undergone by the specimen and its starting length;
- K (N/mm), or modulus of elasticity means the ratio between a specific tension increase and a strain increase evaluated in the range between the values corresponding to 30% and 60% of proportionality limit;
- Tp (N/mm), or proportionality limit means the limit value of tension, beyond which the tension/strain ratio is no more linear.
- T R (N/mm), or breaking limit, the maximum value before breaking.
- sample A At last, on sample A an attenuated total infrared (ATR-FTIR) spectrometry analysis and a Raman spectroscopy analysis were carried out by using a Magna 560 Nicolet spectrophotometer, having an ATR Model 300 Spectra Tech cell. The resulting spectra relating to sample A are shown in Fig. 4.
- ATR-FTIR attenuated total infrared
- sample B (63 mm x 63 mm) was cut out from a human fibrin membrane obtained according to the above-mentioned process, that was sterilized using the STERRAD method (in H 2 O at 45°C) and stored at room temperature.
- sample A also sample B was subjected to mechanical tensile tests and breaking strength tests, as well as to a morphological analysis at the electron microscope, after having determined the thickness of the membrane.
- Example 2 For sample B, the same procedure was followed using the same equipment as in Example 2, for the thickness determination. To check the uniformity level of the considered membrane, thickness measurements were carried out in ten different points of the membrane spaced apart between them and from the edges by about 10 mm. The detected values are given as follows:
- sample B The mechanical properties of sample B were evaluated according to the procedures used in Example 2.
- the rectangular shaped sample C (66 mm x 128 mm) was cut out from a human fibrin membrane obtained according to the above-mentioned process, that was sterilized in autoclave at 120°C and stored at room temperature.
- samples A and B also sample C was subjected to mechanical tensile tests and breaking strength tests, as well as to a morphological analysis at the electron microscope, after having determined the thickness of the membrane.
- sample C the same procedure was followed by using the same equipment as in the Example 2, for determining the thickness. To check the uniformity level of the considered membrane, thickness measurements were carried out in ten different points of the membrane spaced apart between them and from the edges by about 10 mm.
- sample C The mechanical properties of sample C were evaluated by the same procedures used in Example 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002507162A CA2507162A1 (en) | 2002-11-26 | 2003-11-26 | Process for manufacturing fibrin membranes |
US10/536,612 US7348411B2 (en) | 2002-11-26 | 2003-11-26 | Process for manufacturing fibrin membranes and fibrin membranes obtained according to this process |
EP03780655A EP1565514A2 (en) | 2002-11-26 | 2003-11-26 | Process for manufacturing fibrin membranes |
AU2003288532A AU2003288532A1 (en) | 2002-11-26 | 2003-11-26 | Process for manufacturing fibrin membranes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2002A002501 | 2002-11-26 | ||
IT002501A ITMI20022501A1 (en) | 2002-11-26 | 2002-11-26 | ORGANIC CICATRIZING AND HEMOSTATIC DRESSING. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004048449A2 true WO2004048449A2 (en) | 2004-06-10 |
WO2004048449A3 WO2004048449A3 (en) | 2004-08-12 |
Family
ID=32375539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2003/000780 WO2004048449A2 (en) | 2002-11-26 | 2003-11-26 | Process for manufacturing fibrin membranes |
Country Status (6)
Country | Link |
---|---|
US (1) | US7348411B2 (en) |
EP (1) | EP1565514A2 (en) |
AU (1) | AU2003288532A1 (en) |
CA (1) | CA2507162A1 (en) |
IT (1) | ITMI20022501A1 (en) |
WO (1) | WO2004048449A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011138803A1 (en) * | 2010-05-06 | 2011-11-10 | Silfradent S.R.L | Kit for obtaining and processing a material derived from a physiological tissue |
WO2014070881A1 (en) * | 2012-10-30 | 2014-05-08 | The Cleveland Clinic Foundation | Multipurpose membranes, methods for forming, and applications thereof |
US10086110B2 (en) | 2012-10-30 | 2018-10-02 | The Cleveland Clinic Foundation | Multipurpose membranes, methods for forming, and applications thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911440A (en) * | 2005-08-08 | 2007-02-14 | 上海莱士血制品有限公司 | Kit used for forming fiber protein film and its application |
EP2933589A1 (en) | 2014-04-14 | 2015-10-21 | Whirlpool Corporation | A method for controlling a refrigerating unit |
EP3852820A4 (en) * | 2018-09-17 | 2022-06-15 | Board of Regents, The University of Texas System | Compositions and methods for treating bone injury |
US20230277474A1 (en) * | 2020-08-31 | 2023-09-07 | Vitruvian Medical Devices, Inc. | Storage Stable Films Comprising Fibrin and/or Fibrinogen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6368298B1 (en) * | 1997-06-24 | 2002-04-09 | Roberto Beretta | Preparing autologous fibrin glue |
US20020131933A1 (en) * | 1996-01-16 | 2002-09-19 | Yves Delmotte | Biopolymer membrane and methods for its preparation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6010716B2 (en) * | 1976-06-24 | 1985-03-19 | 美浜 久春 | Manufacturing method of reinforced fibrin membrane |
EP0068048B1 (en) * | 1981-06-25 | 1985-06-19 | Serapharm GmbH & Co. KG | Enriched plasma derivative for promoting wound sealing and wound covering |
-
2002
- 2002-11-26 IT IT002501A patent/ITMI20022501A1/en unknown
-
2003
- 2003-11-26 CA CA002507162A patent/CA2507162A1/en not_active Abandoned
- 2003-11-26 EP EP03780655A patent/EP1565514A2/en not_active Withdrawn
- 2003-11-26 WO PCT/IT2003/000780 patent/WO2004048449A2/en not_active Application Discontinuation
- 2003-11-26 AU AU2003288532A patent/AU2003288532A1/en not_active Abandoned
- 2003-11-26 US US10/536,612 patent/US7348411B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020131933A1 (en) * | 1996-01-16 | 2002-09-19 | Yves Delmotte | Biopolymer membrane and methods for its preparation |
US6368298B1 (en) * | 1997-06-24 | 2002-04-09 | Roberto Beretta | Preparing autologous fibrin glue |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011138803A1 (en) * | 2010-05-06 | 2011-11-10 | Silfradent S.R.L | Kit for obtaining and processing a material derived from a physiological tissue |
WO2014070881A1 (en) * | 2012-10-30 | 2014-05-08 | The Cleveland Clinic Foundation | Multipurpose membranes, methods for forming, and applications thereof |
US10086110B2 (en) | 2012-10-30 | 2018-10-02 | The Cleveland Clinic Foundation | Multipurpose membranes, methods for forming, and applications thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2507162A1 (en) | 2004-06-10 |
WO2004048449A3 (en) | 2004-08-12 |
AU2003288532A8 (en) | 2004-06-18 |
AU2003288532A1 (en) | 2004-06-18 |
US7348411B2 (en) | 2008-03-25 |
ITMI20022501A1 (en) | 2004-05-27 |
US20060088577A1 (en) | 2006-04-27 |
EP1565514A2 (en) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pan et al. | Mussel‐and barnacle cement proteins‐inspired dual‐bionic bioadhesive with repeatable wet‐tissue adhesion, multimodal self‐healing, and antibacterial capability for nonpressing hemostasis and promoted wound healing | |
US7098315B2 (en) | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
US2517772A (en) | Neutralized oxidized cellulose products | |
Marreco et al. | Effects of different sterilization methods on the morphology, mechanical properties, and cytotoxicity of chitosan membranes used as wound dressings | |
Razzak et al. | Irradiation of polyvinyl alcohol and polyvinyl pyrrolidone blended hydrogel for wound dressing | |
EP3362110B1 (en) | Haemostatic device | |
Matsuda et al. | Re-freeze dried bilayer artificial skin | |
CZ20032198A3 (en) | Process for preparing collagen sponge, apparatus for separating a portion of collagen foam and elongate collagen sponge | |
US20070009580A1 (en) | Non-adhesive hydrogels | |
US20110071227A1 (en) | Rapidly wetting material containing hydrocolloid, method for the manufacture thereof and use thereof | |
JP2019505338A (en) | Composite biomaterials with controlled release of active ingredients, preparation methods and uses | |
KR20010101167A (en) | Collagen hemostatic foam | |
ES2313445T3 (en) | PROCEDURE FOR THE PREPARATION OF BI- AND THREE-DIMENSIONAL POLYMER ARMS. | |
US20050214277A1 (en) | Suspension comprising fibrinogen, thrombin and alcohol, a method for preparing such a suspension, a method for coating a carrier with such a suspension, a method of drying a coating of a carrier, and a coated collagen sponge | |
WO1998007452A1 (en) | Method of sterilising material for implantation | |
US7348411B2 (en) | Process for manufacturing fibrin membranes and fibrin membranes obtained according to this process | |
BR112014019436B1 (en) | BIODEGRADABLE GAZE AND METHOD TO PRODUCE A BIODEGRADABLE GAZE | |
Ishihara et al. | Photocrosslinkable chitosan: an effective adhesive with surgical applications | |
CN111110920B (en) | Biological patch and preparation method thereof | |
RU2281088C2 (en) | Porous spongy cellulose material for wound treatment | |
JPH0780020A (en) | Wound covering material | |
CN111991611B (en) | Self-repairing hemostatic sponge capable of being adhered and preparation method thereof | |
CN112007202B (en) | Adhesive healing-promoting hemostatic sponge and preparation method thereof | |
CN105688261B (en) | Composite material | |
JP6822760B2 (en) | Hemostatic material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006088577 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10536612 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2507162 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003780655 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003780655 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10536612 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |